

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
02 December 2021 (02.12.2021)



(10) International Publication Number
WO 2021/242728 A1

(51) International Patent Classification:

A61P 35/00 (2006.01) A61K 39/395 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2021/034000

(22) International Filing Date:

25 May 2021 (25.05.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/029,757	26 May 2020 (26.05.2020)	US
63/069,942	25 August 2020 (25.08.2020)	US
63/160,074	12 March 2021 (12.03.2021)	US
63/174,474	13 April 2021 (13.04.2021)	US
63/181,434	29 April 2021 (29.04.2021)	US
63/185,881	07 May 2021 (07.05.2021)	US

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: **FURY, Matthew, G.**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **LOWY, Israel**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **MATHIAS, Melissa, Divya**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **YAMA-DANG, Nazumi, Alice**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US). **FURY, Wen**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).


(74) Agent: **EL HIOUM, Dianna, G.** et al.; Fox Rothschild LLP, 997 Lenox Drive, Lawrenceville, NJ 08648-2311 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

(54) Title: METHODS OF TREATING CERVICAL CANCER BY ADMINISTERING THE PD-1 INHIBITOR ANTIBODY CEMIPIMAB

MEAN CHANGE FROM BASELINE IN GHS/QOL SCALE

MMRM estimates



C, cycle; CI, confidence interval; D, day; GHS, Global Health Status; IC, investigator's choice; LS, least square; MRM, mixed model repeated measure; QoL, quality of life; SE, standard error

FIG. 3

(57) Abstract: The present disclosure provides methods for treating, reducing the severity of, or inhibiting the growth of a tumor or improving overall survival in a cervical cancer patient, wherein the method includes selecting a patient with cervical cancer in need thereof and administering to the patient a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an anti-PD-1 antibody or antigen-binding fragment thereof such as cemiplimab or a bioequivalent thereof). In certain embodiments, the patient has recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

[Continued on next page]

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*